Cognitive
Semax
ACTH(4-10) Pro-Gly-Pro analog
ACTH fragment analog; nootropic
This Semax entry draws on 5 cited sources published 2007 to 2026. The evidence available is graded Russia-Approved + Anecdotal on this site's scale. Dosing is reported as described in the literature rather than as guidance. Sources checked .
At a glance
- Class
- ACTH fragment analog; nootropic
- Drug class
- Cognitive
- Structure
- Heptapeptide Met-Glu-His-Phe-Pro-Gly-Pro
- Route
- Intranasal / SC
- Half-life
- ~5-15 min (intranasal peak)
- Evidence tier
- Russia-Approved + Anecdotal
- Availability
- Research / Intl Rx
- Research depth
- 182 indexed citations →
Mechanism of action
Upregulates BDNF and NGF; modulates dopamine and serotonin systems; neuroprotective
Reported areas of research
Enhanced focus and memory; BDNF elevation; neuroprotection; stroke recovery (Russia-approved)
Items above describe areas studied in published peptide literature, not approved indications. Most peptides catalogued here are not FDA-approved for human use.
Dosage protocols reported in literature
200 mcg intranasal daily (0.1% solution, 2-3 drops per nostril, nootropic starting dose, max 600 mcg/day per Russian clinical literature for stroke and cognitive support)
Reported research dosing only. This is not a clinical recommendation. Consult a qualified clinician before any human use.
Known concerns and limitations
Mild irritability; insomnia; nasal irritation with intranasal use
Compared with
Semax has published head-to-head comparisons with 3 compounds that share its pharmacological class: mechanism, half-life, reported research dosing, evidence tier and regulatory status side by side.
Frequently asked questions
What dosing is reported for Semax in research literature?
Published peptide research reports the following dosing approach for Semax: 200 mcg intranasal daily (0.1% solution, 2-3 drops per nostril, nootropic starting dose, max 600 mcg/day per Russian clinical literature for stroke and cognitive support). This is a research reference, not a clinical recommendation.
How is Semax administered in research?
Semax is administered via the following routes in published studies: Intranasal / SC.
What is the reported half-life of Semax?
The reported half-life of Semax is ~5-15 min (intranasal peak).
Is Semax FDA-approved?
No. Semax is not an FDA-approved drug. Semax was nominated for FDA's bulk drug substance lists, flagged by FDA for possible safety risks, and the nomination was then withdrawn by the party that filed it, which leaves it with no route to lawful compounding rather than with a clean record. FDA's Pharmacy Compounding Advisory Committee (docket FDA-2025-N-6895) evaluated Semax for the 503A Bulks List on 24 July 2026, for cerebral ischemia, migraine, and trigeminal neuralgia; the sources cited here report no outcome. PeptideHelper.org catalog status: Research / Intl Rx.
Sources: FDA: bulk drug substances that may present significant safety risks; FDA meeting notice and agenda; Fierce Pharma, 23 July 2026; Pharmaceutical Executive, 24 July 2026.
What level of evidence supports Semax?
The current evidence base for Semax is best characterised as: Russia-Approved + Anecdotal. See the methodology page for the full evidence-tier rubric.
What side effects are reported for Semax?
Known concerns reported in the literature for Semax include: Mild irritability; insomnia; nasal irritation with intranasal use. Always consult a qualified clinician before any human use.
Is there anyone who should not use Semax?
No formal contraindications are established for Semax, because it is not an FDA-approved medicine and no approved label exists to define them. That is an absence of regulatory review rather than evidence of safety. Reported concerns from the literature are: Mild irritability; insomnia; nasal irritation with intranasal use. Always consult a qualified clinician before any human use.
How does Semax work?
The mechanism of action reported for Semax in the literature: Upregulates BDNF and NGF; modulates dopamine and serotonin systems; neuroprotective.
What is Semax studied for?
Semax has been studied in the published literature for: Enhanced focus and memory; BDNF elevation; neuroprotection; stroke recovery (Russia-approved). These are areas of research, not established clinical uses unless the compound is FDA-approved for them.
What is Semax?
Semax is classified as: ACTH fragment analog; nootropic. Also known as: ACTH(4-10) Pro-Gly-Pro analog.
Studied in combination
Semax appears in the following peptide combinations discussed in research and practitioner literature:
- Nootropic Duo, Focus + anxiolysis without sedation
- Cognitive + Sleep, Day focus / night recovery cycle
Drug class
- Nootropic peptides, see all peptides tagged Nootropic.
Research focus area
All peptides studied for Cognitive, ranked by evidence tier and regulatory status.
Primary sources
- Gusev EI et al. The efficacy of semax in the treatment of patients at different stages of ischemic stroke. Zh Nevrol Psikhiatr Im S S Korsakova 2018. PMID 29798983
- Agapova TY et al. Neurotrophin gene expression in rat brain under the action of Semax, an analogue of ACTH 4-10. Neurosci Lett 2007. PMID 17353092
- Liang Y et al. Multi-Layer Magnetic Shields Based on Fe-Based Nanocrystalline and Co-Based Amorphous Ribbons. Materials (Basel, Switzerland) 2026. PMID 42195624
- Arcos I et al. Digitally Guided Hybrid Maxillary Expansion with Supragingival Mandibular Miniplates for Class III Correction in Late Adolescents: A Pilot Clinical Study. Journal of clinical medicine 2026. PMID 42074872
- Mavrych V et al. Therapeutic peptides in gerontology: mechanisms and applications for healthy aging. Frontiers in aging 2026. PMID 42021992
Open the full interactive PeptideHelper.org reference to compare peptides side-by-side, evaluate stacks, and explore the catalog.
Spot an error or a missing source on this page? Suggest a correction. Corrections are logged and surfaced in the next review.
Loading interactive view…